Browse studies

Find your next paid study

1 recruiting study matching your filters

Early Phase Study to Evaluate the MEK Inhibitor Selumetinib With the MDM2 Inhibitor APG-115 in Patients With Neurofibromatosis Type 1 and Pre-malignant and Malignant Peripheral Nerve Sheath Tumors

This is a phase 0/1/2, multi-site study to evaluate the MEK inhibitor Selumetinib with the MDM2 Inhibitor APG-115 in patients with Neurofibromatosis Type 1 and…

Malignant Peripheral Nerve Sheath Tumor (MPNST)Neurofibromatosis 1 (NF1)Atypical Neurofibroma

Estimated

~$10 – $7,500

AeRang KimNCT06735820